ReviewFrontiers in immunology2025
Gene expression silencing therapy in tumors, focus on gastrointestinal and genitourinary tumors.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Targeting lncRNAs to Overcome Cancer Therapy Resistance: Advances in RNA Therapeutics and Delivery Strategies.Cancers · 2026Review
- Exosome-loaded nanoradiosensitizers in radiotherapy for preventing post-irradiation tumor recurrence: mechanisms, preclinical evidence, and translational challenges.Discover nano · 2026Review
- PDIA6 promotes the cell proliferation of ESCC by enhancing the disulfide bond formation in TRAF4.Cellular & molecular biology letters · 2026Article
- MicroRNA-based integrated diagnosis and therapy for GBM: current status and advances.Frontiers in immunology · 2026Review
- Targeting β-catenin: PROTACs and precision degraders for Wnt-driven cancers.Frontiers in oncology · 2026Review
- Hybrid Nanocarriers for Cancer Therapy: Advancements in Co-Delivery of Gene Therapy and Immunotherapy.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision oncology has seen significant progress with oligonucleotide-based therapies, which provide a novel approach to gene expression silencing. These therapies, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and microRNAs (miRNAs), target specific genetic sequences with high precision. They offer promising solutions for cancers resistant to conventional treatments due to their ability to modulate previously "undruggable" targets and their reduced toxicity. However, challenges such as susceptibility to degradation, poor cellular uptake, and off-target effects have hindered their clinical application. Advances in chemical modifications and delivery systems, like lipid nanoparticles and GalNAc conjugates, have improved the stability and efficacy of these therapies. This review discusses the structural features, mechanisms of action, and clinical applications of ASOs, siRNAs, and miRNAs, focusing on gastrointestinal and genitourinary cancers. We highlight successful oncology applications, such as siRNA-based therapies targeting specific oncogenes, which have shown promise in clinical trials. Continued advancements in this field are paving the way for more effective and safer cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.